In total, 62% of patients with CAD received statin monotherapy; 32% received statins in combination with other lipid-lowering agents; 32% received aspirin monotherapy, 10% received P2Y12 inhibitor monotherapy; and 52% received dual anti-platelet therapy. This evidence concerns the gene P2RY12 and coronary artery disorder.